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Abstract
We updated the meta-analysis published by McDonald et al. 
[Chest 2002; 122; 1535–1542] by reviewing the effectiveness 
of air purification for the treatment of home-related allergic 
asthma (dust mite, dog, cat, and cockroach). We analysed the 
trials included by McDonald et al. as well as studies pub-
lished since 2000. Data on asthma symptoms scores (ASS), 
medication use, forced expiratory volume in 1 s as a percent-
age of the predicted value (FEV1 %pred), histamine provoca-
tive concentration causing a 20% reduction in FEV1 (PC20), 
Asthma Quality of Life Questionnaire (AQLQ) scores, and 
fractional exhaled nitric oxide (FeNO) levels were extracted. 
The effectiveness was examined using metafor (registered in 
Prospero CRD42019127227). Ten trials including a total of 
482 patients (baseline characteristics: mean FEV1 %pred 
83.2%, I2 = 96.7%; mean PC20 4.93 mg/mL, I2 = 44.0%; mean 
AQLQ 4.67 [max. 7], I2 = 93.7%; mean FeNO 36.5 ppb, I2 = 0%) 
were included. We assessed the mean differences in the 
AQLQ scores as +0.36 (95% CI 0.10 to 0.62, p = 0.01, n = 302, 
I2 = 0%) and the FeNO levels as –6.67 ppb (95% CI –10.56 to 
–2.77, p = 0.0008, n = 304, I2 = 0%). The standardised mean 
differences in all other health outcomes were not significant 
(ASS –0.68, p = 0.20; medication use: –0.01, p = 0.94; FEV1 
%pred –0.11, p = 0.34; PC20 +0.24, p = 0.53). We found statis-
tically significant mean differences in the AQLQ scores and 
FeNO levels in patients with predominantly mild to moder-
ate asthma at baseline. A large trial reported great improve-
ment in the subgroup of patients receiving Global Initiative 
for Asthma step 4 therapy. We recommend that future stud-
ies on air purification focus on patients with severe and poor-
ly controlled allergic asthma. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Respiratory allergy is a public health problem that af-
fects approximately 400 million people [1]. The most 
common home-related respiratory allergies result from 
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house dust mite, dog, cat, and cockroach allergen (Global 
Initiative for Asthma, GINA, 2018). Therapies such as 
pharmacological treatment, immunotherapy, and avoid-
ance of indoor allergen exposure have been developed for 
the treatment of allergic asthma [2]. Evidence of clinical 
benefits of textile-based avoidance strategies has not been 
demonstrated in rigorous systematic reviews [3–5]. In a 
scoping review, Boven et al. [6] observed potential success 
with the strategy of air purification for the treatment of 
house dust mite allergy-related asthma. Previously, Mc-
Donald et al. [7] reported improvements in asthma symp-
tom scores (ASS) associated with air purification in a 
small patient subgroup (n = 88).
Whether the purification of indoor air is of clinical im-
portance in patients with asthma remains an unanswered 
question. An allergic reaction is provoked in the upper 
airways after the deposition of aerosol particles in the ep-
ithelium. The faecal pellets of house dust mites are very 
small in size, at 10–40 μm (mean 22 μm), and decrease 
when they are partially degraded over time (diameter 
> 0.5 μm) [8, 9]. A large proportion of cat and dog aller-
gens are smaller than 2 μm in diameter and coagulate in 
the air to other aerosol dust [10]. The particle size of cock-
roach allergens is mainly > 10 μm [11]. Industrial branch-
es have developed specific filters (high-efficiency particu-
late air, HEPA, filters) that capture very small airborne 
particles with high efficiency (at least 85–99.999995% of 
particles with a diameter of 0.3 μm) [12]. These HEPA 
filters are applied in residential products such as housing 
ventilation units, mobile air cleaners, nocturnal temper-
ature-regulated laminar airflow units, and vacuum clean-
ers. The strategy of air purification has a potential advan-
tage over a textile-based control strategy because the for-
mer strategy traps airborne allergens emitted from clothes 
as well as emissions from indoor textiles. This advantage 
may explain the clinical potential of the air purification 
strategy. As the current evidence on the clinical effective-
ness of the air purification strategy is based on small sam-
ple sizes and was obtained many years ago, there is a need 
to update the evidence base, as new devices for purifying 
the nocturnal breathing zone have been introduced [13, 
14].
This study updates the existing systematic review by 
McDonald et al. [7] entitled “Effect of Air Filtration Sys-
tems on Asthma” by reviewing the clinical effectiveness 
of the air purification strategy for the treatment of home-
related allergic asthma (house dust mite allergy, dog al-
lergy, cat allergy, and cockroach allergy).
Methods
Reference Search
The starting point of this study was the systematic review by 
McDonald et al. [7]. This meta-analysis included ten trials. An up-
dated search of the literature published since January 2000 was 
performed in EMBASE, MEDLINE, and the Cochrane Central 
Register of Controlled Trials (CENTRAL). The trials were limited 
to peer-reviewed publications in the English language, and (Con-
gress) abstracts were excluded from the analysis. The titles and/or 
abstracts of the studies retrieved during the search were screened 
(with Endnote) by the first author (F.E.v.B.) to identify randomised 
trials that met the inclusion criteria outlined below. The full texts 
of the potentially included trials were retrieved and assessed for 
inclusion by the first (F.E.v.B.) and second (N.W.d.J.) authors. Any 
ambiguities in the selections were resolved by discussion. The in-
clusion criteria were as follows:
 − Type of study: randomised controlled trials with blinding.
 − Intervention: housing or mobile ventilation systems, including 
HEPA filters but not vacuum cleaners.
 − Participants: participants with physician-diagnosed bronchial 
allergic asthma. These participants had their sensitisation as-
sessed by either skin testing or serum assays for specific IgE 
antibodies (house dust mite allergy, dog allergy, cat allergy, and 
cockroach allergy). The asthma assessment included a history 
of asthma symptoms and a pulmonary function test.
 − Controls: participants who received a placebo or no treatment.
Data Extractions and Outcomes
The data were extracted by the first author (F.E.v.B.). The trials 
included in McDonald et al. [7] were re-extracted, as this review 
presented only the results but not the extracted data. The data 
extractions yielded the following: characteristics of the study pop-
ulation including the baseline data; type of intervention and the 
control; study methodology, and outcomes. Missing data were 
requested from the study authors. A second author (N.W.d.J.) ver-
ified the selections and the data extraction conducted by the first 
author. Any ambiguities in the selection and the extraction were 
resolved by discussion.
The main outcome(s) were: the asthma symptom score; the 
number of patients with improved outcomes; medication use; 
forced expiratory volume in 1 s as a percentage of the predicted 
value (FEV1 %pred); provocative concentration that causes a 20% 
reduction in FEV1 (PC20); Asthma Quality of Life Questionnaire 
(AQLQ) score, and the fractional exhaled nitric oxide (FeNO) lev-
el. Additional outcomes included: the mite allergen load from the 
mattress (μg/g dust); type of patient (child or adult), and the pres-
ence of primary and cosensitisation. These additional outcomes 
were all tested as possible explanatory variables in the presence of 
at least ten trials.
For the ASS, the PC20, and the AQLQ scores, the final values 
were extracted (following Egbewale et al. [15]). The change scores 
were extracted for FEV1, medication use, and FeNO level. We de-
fined the direction of changes as positive for an increasing FEV1 
and negative for a decreasing FeNO level and medication use.
Risk of Bias (Quality) Assessment
The risk of bias was assessed for the following domains: se-
quence generation, allocation concealment, blinding, incomplete 
outcome data, and selective outcome reporting. The assessment 
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was performed by the first author (F.E.v.B.) with the Review Man-
ager (RevMan) computer program version 5.3 (the Cochrane Col-
laboration, 2014; Nordic Cochrane Centre, Copenhagen, Den-
mark). A second author (N.W.d.J.) verified the assessments of the 
first author by considering a sample. Any ambiguities in the assess-
ments were resolved by discussion.
Strategy for Data Synthesis
The effect size was set to the standardised mean difference, ex-
cluding the number of patients showing improvement (risk ratio). 
We chose the mean difference as the effect size in cases in which 
the outcomes were all measured in the same manner (AQLQ and 
FeNO). First, the overall effect of the health outcomes was esti-
mated by a random-effects meta-analysis. Additionally, the I2 was 
calculated for examining heterogeneity in the outcomes. In the ab-
sence of heterogeneity (I2 = 0), a fixed-effects model was used. The 
explanatory variables of interest included the primary sensitisation 
(house dust mite allergy, dog allergy, cat allergy, or cockroach al-
lergy), the mite allergen load from the mattress at baseline, possible 
confounding by the type of patient (child/adult), and the presence 
of cosensitisation. These outcomes were analysed for a preferred 
minimum of ten trials per variable [16]. All the calculations were 
performed with the metafor package in R [17, 18]. The level of sig-
nificance was set to α = 0.05.
Results
Selection of the References
We selected and included studies in two groups of 
publications. First, we screened the ten trials included in 
the meta-analysis by McDonald et al. [7]. Three trials 
were excluded for a lack of or only partial reporting on 
the treatment of asthma [19, 20] or reporting incomplete 
data [21]. The remaining seven trials were included in the 
analysis [22–28].
The second group consisted of studies identified in our 
updated search (Fig. 1) [29]. We identified a total of 1,000 
titles and abstracts. A total of 971 titles were excluded for 
lacking randomisation and/or blinding regarding the ef-
fectiveness of air purification. Twenty-nine potentially 
relevant titles were selected for inclusion. We excluded 
twenty-six full-text articles for not meeting our inclusion 
criteria (online suppl. Table; for all online suppl. materi- 
al, see www.karger.com/doi/10.1159/000506284). Three 
full-text articles were included in the analysis [13, 30, 31]. 
In total, ten full-text articles were included in the meta-
analysis.
Description of the Trials and the Baseline 
Characteristics
Ten trials published between 1973 and 2012 reported 
the treatment of asthma by air purification (Table 1). In 
four trials, the primary sensitisation was a pet allergy [13, 
27, 28, 30]; five trials reported patients with house dust 
mite allergy [22–26], and one trial reported a mix of pri-
mary antigens [31]. None of the trials reported monosen-
sitisation in the included patients. One trial [31] present-
ed data on the specific IgE during the trial. Three trials 
reported the treatment of children with allergic asthma; 
the others reported the treatment of adults or both chil-
Records identified through
database searching
(n = 1,000)
Additional records identified
through other sources
(n = 0)
Records after duplicates removed
(n = 1,000)
Records screened
(n = 1,000)
Records excluded
(n = 971)
Full-text articles assessed
for eligibility
(n = 29) 
Full-text articles excluded, with reasons:
- Not investigating an HEPA filter (n = 3)
- Not treating asthma (n = 1)
- Only abstract (n =  9)
- Not an RCT (n = 13)
Studies included in
quantitative synthesis
(meta-analysis)
(n = 3)
Fig. 1. Flow chart of the reference search.
van Boven/de Jong/Braunstahl/Arends/
Gerth van Wijk
Int Arch Allergy Immunol4
DOI: 10.1159/000506284
dren and adults. Four trials studied nocturnal laminar 
airflow in the breathing zone; the other six trials studied 
the use of a home ventilation or mobile device with a 
HEPA filter. Only one trial reported on the airborne al-
lergen exposure [28], five other trials reported on dust 
exposure or allergen load at baseline [24–27, 30]. In the 
trial by Warburton et al. [25] only the data on FEV1 %pred 
at baseline were available for analysis. In five trials, the 
mean FEV1 %pred was 83.2% (I2 = 96.7%, n = 346). The 
mean PC20 was 4.93 mg/mL (I2 = 44.0%, 2 trials, n = 29), 
the mean AQLQ score was 4.67 (max. 7; I2 = 93.7%, 2 tri-
als, n = 304), and the mean FeNO level was 36.5 ppb (I2 = 
0%, 2 trials, n = 304). For the ASS and medication use, we 
had no (quantitative) data available at baseline. Ten trials 
reported on the use of medication at baseline. In four tri-
als, the change in the use of medication was a primary 
outcome for measuring effectiveness [22, 25, 26, 28]. Two 
investigations instructed their patients not to change 
their medication [23, 27]. In two trials [13, 31], patients 
were allowed to use more medication. The risk of bias was 
judged as predominantly unclear with a low risk of bias 
in blinding (Fig. 2).
Synthesis of the Efficacy Results
Four trials reported ASS as outcomes. We assessed 
the standardised mean difference in the ASS as –0.68 
(95% CI –2.21 to 0.85; p = 0.20; n = 77; I2 = 51.0%; Fig. 3). 
The standardised mean difference in medication use 
was –0.01 (95% CI –0.22 to 0.21; p = 0.94; n = 401; I2 = 
0%, 4 trials; Fig. 4). In three trials, the standardised mean 
difference in FEV1 %pred was –0.11 (95% CI –0.34 to 
0.12; p = 0.34; n = 324; I2 = 0%; Fig. 5). Four trials re-
ported on the PC20, with a standardised mean difference 
of +0.24 (95% CI –0.85 to 1.33; p = 0.53; n = 98; I2 = 
Table 1. Characteristics of the included studies
Trial Use of a HEPA filter Subjects Primary allergy Health outcomes extracted
Zwemer [22], 1973 Nocturnal laminar airflow Child House dust mite ASS
Verrall [23], 1988 Nocturnal laminar airflow Adult House dust mite Medication use
Antonicelli [23], 1991 Mobile device Adult House dust mite ASS, medication use, FEV1 %pred, PC20
Warburton [24], 1994 Mobile device Adult House dust mite FEV1 %pred
Van der Heide [26], 1997 Mobile device Adult House dust mite PC20
Wood [28], 1998 Mobile device Adult Cat ASS, medication use
Van der Heide [27], 1999 Mobile device Child Cat or dog Medication use, PC20
Pedroletti [13], 2009 Nocturnal laminar airflow Adult Cat or dog AQLQ score, FeNO level
Sulser [30], 2009 Mobile device Adult Cat or dog PC20
Boyle [31], 2012 Nocturnal laminar airflow Adult House dust mite  
or cat
Medication use, FEV1 %pred, AQLQ 
score, FeNO level
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60.0%; Fig. 6). The AQLQ scores were reported in two 
trials. We assessed the mean difference in the AQLQ 
scores as +0.36 (95% CI 0.10 to 0.62, p = 0.01, n = 302, 
I2 = 0%; Fig. 7). This positive increase was strongly in-
fluenced by the large trial by Boyle et al. [31] (weight 
77%). The mean difference in the FeNO level was –6.67 
ppb (95% CI –10.56 to –2.77, p = 0.008, n = 304, I2 = 0%; 
Fig. 8). None of the included trials reported on whether 
the physician-diagnosed numbers improved. Overall, 
the number of trials available was too small to allow any 
subgroup analysis.
Discussion
We reviewed the clinical effectiveness of the air purifi-
cation strategy for the treatment of home-related allergic 
asthma in ten trials. The mean differences in the AQLQ 
score (MD = +0.36; p = 0.01) and the FeNO level (MD = 
–6.67; p = 0.008) were statistically significant, suggesting 
that asthma patients may benefit from air purification. 
These results were obtained in patients with predomi-
nantly mild to moderate asthma outcomes at baseline 
(the FEV1 %pred, the AQLQ score, and the FeNO level). 
Verrall, 1988
Author, year Sample sizes
n1
13
n2
13 –0.30 (–1.07, 0.47)
Mean std. diff. med. use (95% CI)
Antonicelli, 1991 9 9 –0.17 (–1.10, 0.75)
Wood, 1998 18 17
–2.5
–0.05 (–0.71, 0.61)
Boyle, 2012 189 93 0.04 (–0.21, 0.29)
RE model for all studies: I2 = 0.0% –0.01 (–0.22, 0.21)
–1 0
Standardised mean difference
1
Author, year Sample sizes
n1 n2
Mean std. diff. FEV1 (95% CI)
Antonicelli, 1991 9 9 0.17 (–0.75, 1.10)
Warburton, 1994 12 12
–2.5
0.00 (–0.80, 0.80)
Boyle, 2012 189 93 –0.14 (–0.39, 0.11)
FE model for all studies: I2 = 0.0% –0.11 (–0.34, 0.12)
–1 0
Standardised mean difference
1
Author, year Sample sizes
n1 n2
Mean std. diff. ASS (95% CI)
Zwemer, 1973 12 12 –1.43 (–2.33, –0.54)
Antonicelli, 1991 9 9
–2.5
–0.29 (–1.22, 0.64)
Wood, 1998 18 17 –0.39 (–1.06, 0.28)
RE model for all studies: I2 = 51.0% –0.68 (–2.21, 0.85)
–1 0
Standardised mean difference
1
Fig. 3. Forest plot of the standardised mean 
differences in the ASS.
Fig. 4. Forest plot of the standardised mean 
differences in medication use.
Fig. 5. Forest plot of the standardised mean 
differences in the FEV1 %pred.
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The overall airway hyperresponsiveness was mild at base-
line, according to the classification by Cockcroft et al. 
[32]. The risk of bias in the trials was predominantly 
judged unclear; however, blinding has a low risk of bias.
The strength of this meta-analysis was the rigorous se-
lection of trials and extraction of data. We decided a pri-
ori whether to extract change or final values considering 
the statistical notes by Egbewale et al. [15]. In our study, 
we excluded some trials that were included by McDonald 
et al. [7] due to a critical process in extracting the data. 
For instance, they included the ASS by Reisman et al. [20]. 
After a critical review of this paper, we decided not to ex-
tract these data as only 11 of 32 patients were diagnosed 
with asthma; thus, we excluded this trial from the analy-
sis. We noticed that this trial was also excluded for the 
same reason in the meta-analysis by Gøtzsche and Johan-
sen [3]. While the previously analysed trials were quite 
old, the recent trials included the use of validated out-
comes such as the AQLQ score [33]. In patients with mild 
to moderate disease, we observed small (not reaching the 
minimum clinically important difference) but significant 
improvements in the AQLQ scores and FeNO levels. This 
effect could possibly be stronger in patients with severe 
asthma than in those with mild to moderate asthma. This 
possible tendency is well presented in the large trial by 
Boyle et al. [31]. They studied the effectiveness of the Pro-
Antonicelli, 1991
Author, year Sample sizes
n1
9
n2
9 –0.12 (–1.05, 0.80)
Mean std. diff. PC20 (95% CI)
Van der Heide, 1997 15 15 0.26 (–0.46, 0.98)
Van der Heide, 1999 10 10
–2.5
1.29 (0.32, 2.25)
Sulser, 2009 16 14 –0.31 (–1.03, 0.41)
RE model for all studies: I2 = 60.0% 0.24 (–0.85, 1.33)
–1 0
Standardised mean difference
1
Author, year Sample sizes
n1 n2
Mean diff. AQLQ (95% CI)
Pedroletti, 2009 10 10
–2
0.54 (–0.01, 1.09)
Boyle, 2012 189 93 0.31 (0.01, 0.61)
FE model for all studies: I2 = 0.0% 0.36 (0.10, 0.62)
0
Mean difference
2
Author, year Sample sizes
n1 n2
Mean diff. FeNO (95% CI)
Pedroletti, 2009 11 11
–20
–6.40 (–11.30, –1.50)
Boyle, 2012 189 93 –7.13 (–13.55, –0.71)
FE model for all studies: I2 = 0.0% –6.67 (–10.56, –2.77)
0
Mean difference
10
Fig. 6. Forest plot of the standardised mean 
differences in the PC20.
Fig. 7. Forest plot of the mean differences 
in the AQLQ scores.
Fig. 8. Forest plot of the mean differences 
in the FeNO levels.
Air Purification for the Treatment of 
Allergic Asthma
7Int Arch Allergy Immunol
DOI: 10.1159/000506284
texo system (a nocturnal temperature-controlled laminar 
airflow) and reported the outcomes of the use of medica-
tion, FEV1 %pred, AQLQ scores, and FeNO levels. They 
differentiated the AQLQ score, their primary outcome, 
and the asthma status defined by the treatment intensity 
of GINA and the asthma control test (ACT). After a 1-year 
treatment period, Boyle et al. [31] reported an AQLQ 
score difference of +0.31 (p = 0.04) in all the studied pa-
tients (n = 282). When limited to the patients classified as 
requiring GINA step 4 therapy (GINA 4) at baseline, the 
difference became +0.47 (p = 0.04, n = 129). In the patients 
receiving GINA 4 with poor control (ACT < 18), the dif-
ference in the AQLQ score was +0.70 (p = 0.02, n = 87). 
Additionally, in the patients with a high FeNO level at 
baseline, the same tendency was reported by Boyle et al. 
[31] (mean difference in FeNO –29.7 ppb, p = 0.001). 
The limitation of this meta-analysis was the relatively 
small number of trials included in the analysis. Our update 
did not result in many new included trials. In total, we in-
cluded the same number of trials (n = 10) as McDonald et 
al. [7] included in their earlier meta-analysis. We had to 
exclude three trials that were included by McDonald et al. 
[7] because of a lack of reporting on the treatment of asth-
ma or incompleteness of the data. McDonald et al. [7] pre-
viously reported “a small but statistically significant differ-
ence in total symptoms associated with use of domestic air 
filters.” They did not find benefits associated with medica-
tion use or morning peak flow values. In our update, we 
did not find a significant difference for the ASS outcome. 
The significance reported by McDonald et al. [7] was based 
on an analysis by the fixed-effects model. As the ASS 
showed moderate heterogeneity (I2 = 51%), we introduced 
the random-effects model and the significance was lost. 
The use of domestic HEPA filters will also be of relevance 
in the treatment of non-allergic asthma, for instance by fil-
tering indoor air pollution. As we included only trials on 
the treatment of allergic asthma, this possible issue did not 
bias our results. The description of the allergen exposure 
differed in the trials and was sometimes poorly presented. 
Therefore, we could not analyse the degree of the exposure, 
and also cannot exclude the possibility that a variation of 
allergens from other sources affected the results.
The significant differences we found were both a result 
of trials sponsored by Airsonett AB (Angelholm, Swe-
den). One of these trials [31] was predominantly respon-
sible for the positive AQLQ score analysis and was judged 
as having a risk of bias in randomisation. Their treatment 
group was twice the size of the control group. In principle, 
this creates a risk of selection bias as recruiters could 
“guess with greater than a 50% probability what the next 
treatment allocation will be” [34]. In their report, we did 
not find indications for baseline imbalances biasing the 
estimates. Another issue of relevance in both trials on the 
Protexo system is the possibility of changes in medication 
use. Pedroletti et al. [13] reported that “inhaled, short-
acting beta-2 agonists were allowed as rescue treatment.” 
Boyle et al. [31] instructed that the patients “asthma med-
ication were kept unchanged for the first 3 months, and 
thereafter adjusted to optimise asthma control.” We can-
not exclude the possibility that these instructions con-
founded the significant results we found. Overall, the re-
sults require independent repeating, with careful moni-
toring of allergen exposure.
Other studies on the Protexo system resulted in (some) 
clinical benefits. Schauer et al. [35] observed reduced 
asthma exacerbation and hospitalisations in an observa-
tional study in patients with predominantly difficult-to-
control asthma. In a recent pilot study, Gore et al. [36] 
reported the potential for the use of the Protexo system as 
an add-on to standard pharmacological treatment in chil-
dren with difficult-to-control atopic dermatitis. These re-
sults also reflect the need to study patients with severe and 
uncontrolled conditions.
In brief, we reviewed the clinical effectiveness of the air 
purification strategy for the treatment of home-related 
allergic asthma (house dust mite allergy, dog allergy, cat 
allergy, and cockroach allergy). We found statistically sig-
nificant mean differences in the AQLQ scores and FeNO 
levels in patients with predominantly mild to moderate 
asthma at baseline. A large underlying trial [31] showed 
potentially great improvement in the AQLQ scores in the 
subgroup of patients receiving GINA 4 therapy with poor 
control. Future studies on air purification strategies with 
rigorous trial designs that focus on patients with severe 
and poorly controlled allergic asthma are warranted.
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